Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FLUVOXAMINE FOR SYSTEM SUITABILITY CRS (1 MG)

FLUVOXAMINE FOR SYSTEM SUITABILITY CRS (1 MG)

61718-82-9

DISCOVER
FLUVOXAMINE MALEATE CRS (5 MG)

FLUVOXAMINE MALEATE CRS (5 MG)

61718-82-9

DISCOVER
CITALOPRAM FOR SYSTEM SUITABILITY CRS (0.065 MG)

CITALOPRAM FOR SYSTEM SUITABILITY CRS (0.065 MG)

59729-32-7

DISCOVER
ISOFLURANE CRS (1.4 ML)

ISOFLURANE CRS (1.4 ML)

26675-46-7

DISCOVER
LIOTHYRONINE FOR PEAK IDENTIFICATION CRS (0.0046 MG)

LIOTHYRONINE FOR PEAK IDENTIFICATION CRS (0.0046 MG)

55-06-1

DISCOVER
METHYLTESTOSTERONE FOR SYSTEMSUITABILITY CRS (10 MG)

METHYLTESTOSTERONE FOR SYSTEMSUITABILITY CRS (10 MG)

58-18-4

DISCOVER
MIANSERIN FOR SYSTEM SUITABILITY CRS (1.01 MG)

MIANSERIN FOR SYSTEM SUITABILITY CRS (1.01 MG)

21535-47-7

DISCOVER
SERTRALINE FOR PEAK IDENTIFICATION CRS (5.4 MG)

SERTRALINE FOR PEAK IDENTIFICATION CRS (5.4 MG)

79559-97-0

DISCOVER
SERTRALINE FOR SYSTEM SUITABILITY CRS (6.2 MG)

SERTRALINE FOR SYSTEM SUITABILITY CRS (6.2 MG)

79559-97-0

DISCOVER
STREPTOKINASE FOR SYSTEM SUITABILITY CRS (30 µL)

STREPTOKINASE FOR SYSTEM SUITABILITY CRS (30 µL)

NA

DISCOVER
TRIAMTERENE IMPURITY B CRS (0.5 MG)

TRIAMTERENE IMPURITY B CRS (0.5 MG)

NA

DISCOVER
BISOPROLOL FOR PEAK IDENTIFICATION CRS (1.007 MG)

BISOPROLOL FOR PEAK IDENTIFICATION CRS (1.007 MG)

104344-23-2

DISCOVER